November 6, 2006 – Quintiles Transnational Corp. today announced that Paula Brown Stafford, Executive Vice President, Global Data Management, has been elected to the Board of Directors of CDISC, an industry consortium that leads the development of data standards to improve medical research.

October 24, 2006 – Solvay Pharmaceuticals has renewed for another five years its clinical development strategic alliance with Quintiles, first signed in 2001, Solvay Pharmaceuticals and Quintiles Transnational Corp. announced today. The renewal reflects the alliance's success in accelerating development of Solvay's product portfolio and improving efficiency.

October 16, 2006 – Quintiles Transnational Corp. today announced plans to open a central lab in Mumbai, India, further expanding the company’s global network of labs that support global and regional clinical trials.

October 2, 2006 – Quintiles Transnational Corp. today announced that John Ratliff has been appointed as its new Chief Operating Officer, effective immediately.  He will be responsible for directing Quintiles’ daily global operations and will report to Chairman and Chief Executive Officer, Dennis Gillings, CBE.  Ratliff also has been elected to the Quintiles Transnational Corp. Board of Directors.~LT~br /~GT~

August 8, 2006 – Quintiles Transnational Corp. today announced the expansion of its global data management network with the opening of a clinical data processing center in Williamston, N.C. The center will provide up to 70 new jobs in the eastern region of the state and build additional capacity for customers seeking services provided by U.S.-based staff.

August 1, 2006 – Steven M. Niedelman, formerly deputy associate commissioner for Regulatory Operations for the U.S. Food and Drug Administration, has joined Quintiles Consulting as executive vice president, Quintiles Transnational Corp. announced today.

July 24, 2006-New unit concentrates expertise in adaptive design, other innovative statistical approaches to help sponsors

June 6, 2006-Quintiles Transnational Corp. has announced that its Quintiles East Asia subsidiary has been named the Asia Pacific region's Multinational Clinical Trials Service Provider of the Year and Multinational CRO of the Year by the consulting firm Frost & Sullivan.

May 11, 2006 - Quintiles Transnational today announced the launch of its expanded strategic partnering group under the NovaQuest™ brand and, to further NovaQuest's mission, an alliance with TPG-Axon Capital, a global investment firm with over $5.8 billion in equity capital.

March 31, 2006 – Quintiles Transnational Corp. today announced that it has completed new credit facility arrangements.

March 29, 2006 – Quintiles Transnational Corp. today announced the appointment of Yoh Narimatsu as President and Chief Executive Officer of Quintiles Transnational Japan K.K. (Quintiles Japan) effective April 1.

March 21, 2006 – Quintiles Transnational Corp., the world's leading pharmaceutical services organization, today announced it has donated $100,000 to the Seattle Vaccine Research Fund (SVRF) to support anti- retroviral treatment for HIV vaccine trial participants who become infected during vaccine studies.

March 17, 2006 – Quintiles Transnational Corp. ("Quintiles") and Pharma Services Intermediate Holding Corp. ("Holding;" each of Holding and Quintiles, is referred to as a "Company") today announced that, in connection with the previously announced tender offer and consent solicitation for any and all of Quintiles' outstanding $450.0 million aggregate principal amount 10% senior subordinated notes due 2013 (CUSIP Nos. 748767 AE0 and 748767 AD2)(the "Subordinated Notes") and any and all of Holding's outstanding $219.0 million aggregate principal amount at maturity 11.5% senior discount notes due 2014 (CUSIP No. 71711W AB6)(the "Discount Notes"), the requisite consents have been received to approve certain amendments to the indentures under which the respective Notes were issued.

March 6, 2006 – Quintiles Transnational Corp. today announced that it is pursuing plans to borrow $1.47 billion under new credit facility arrangements.

March 3, 2006 – Quintiles Transnational Corp. today announced that it and Pharma Services Intermediate Holding Corp. ("Holding;" each of Holding and Quintiles, is referred to as a "Company") have commenced a cash tender offer for any and all of Quintiles' outstanding $450.0 million aggregate principal amount 10% senior subordinated notes due 2013 (CUSIP Nos. 748767 AE0 and 748767 AD2) (the "Subordinated Notes") and any and all of Holding's outstanding $219.0 million aggregate principal amount at maturity 11.5% senior discount notes due 2014 (CUSIP No. 71711W AB6) (the "Discount Notes"). The Subordinated Notes and the Discount Notes are collectively referred to as the "Notes." In connection with the cash tender offer, each Company is also soliciting consents to amend the indentures under which the respective Notes were issued to eliminate or make less restrictive most of the restrictive covenants contained in the indentures and amend certain related provisions. ~LT~br /~GT~